Related by context. All words. (Click for frequent words.) 79 secondary efficacy endpoints 75 secondary endpoints 71 primary endpoints 70 clinical endpoints 70 primary endpoint 70 primary efficacy endpoint 69 efficacy endpoint 66 secondary endpoint 66 primary efficacy endpoints 66 prospectively defined 65 noninferiority 65 composite endpoint 64 tolerability 64 Secondary endpoints 64 alvimopan 64 elagolix 64 pharmacodynamic 63 prespecified 63 non inferiority 62 pharmacodynamic endpoints 62 Azixa 62 efficacy 62 rALLy trial 62 placebo controlled clinical trials 62 pharmacokinetics PK 62 pharmacokinetic PK 61 viral kinetic 61 GAMMAGARD 61 EFAPROXYN 61 ruxolitinib 61 forodesine HCl 61 efficacy tolerability 61 Primary endpoints 61 viral kinetics 61 active comparator 61 TELCYTA 61 subgroup analyzes 61 PROPEL trial 61 SILENOR TM 61 PREZISTA r 61 Rasilez Tekturna 61 nonclinical studies 61 AZILECT R 60 MAP# 60 dosing regimens 60 AzaSite Plus 60 pain palliation 60 Androxal TM 60 tecarfarin 60 dosage regimens 60 Allovectin 7 ® 60 phase IIb clinical 60 pharmacokinetic parameters 59 favorable pharmacokinetic profile 59 riociguat 59 INC# 59 BrachySil 59 Secondary efficacy endpoints 59 Phase Ib 59 clinically meaningful 59 bicifadine 59 MEND CABG II 59 teriflunomide 59 TRITON TIMI 59 Phase 2b study 59 placebo controlled studies 59 ataluren 59 posaconazole 59 INCB# [001] 59 placebo controlled trials 59 NLX P# 59 pharmacokinetic profiles 59 dose limiting toxicities 59 mapatumumab 59 phase IIa 58 ACTEMRA TM 58 urocortin 2 58 #D#C# 58 tolerability profiles 58 NP2 Enkephalin 58 pharmacokinetic PK profile 58 analgesic efficacy 58 pharmacokinetic 58 romiplostim 58 pharmacodynamic PD 58 phase Ib 58 nab paclitaxel 58 desvenlafaxine succinate 58 bosentan 58 Phenoptin 58 Dacogen injection 58 tolerability profile 58 Entereg R 58 STRIDE PD 58 Xanafide 58 INCB# [003] 58 exploratory endpoints 58 prespecified criteria 58 ACTEMRA 58 AZD# 58 GSK# [001] 58 Hyphanox 58 Aurexis 58 talactoferrin 58 SILENOR 58 AeroLEF 58 PRIMO CABG 58 achieve statistical significance 58 Azedra 58 Phase Ib study 58 neratinib 58 eculizumab 58 TAXUS VI 58 custirsen 58 PXD# 58 CCX# 58 Exelixis compounds 58 Zenvia 58 phase IIa clinical 58 PS# [001] 58 Neuradiab 58 phase IIb 58 secondary efficacy endpoint 58 Proellex TM 58 lintuzumab 58 pharmacokinetics pharmacodynamics 58 catheter occlusion 58 fosbretabulin 58 Chemophase 58 preclinical efficacy 58 Phase Ia 58 evaluable 58 surrogate endpoint 58 randomized Phase 2b 58 Androxal ® 58 statistical significance 58 pharmacokinetic equivalence 58 telbivudine 58 trials RCTs 58 Clolar ® 57 brivaracetam 57 SinuNase TM 57 picoplatin 57 HCV SPRINT 57 prucalopride 57 RE LY ® 57 orBec 57 dimebon 57 inhibitor RG# 57 Phase 2a trial 57 UPLYSO 57 CIMZIA TM certolizumab pegol 57 KRN# 57 DSMB 57 CIMZIA ™ 57 tanespimycin 57 pharmacodynamic parameters 57 pharmacokinetic studies 57 oral ridaforolimus 57 PEG PAL 57 Cloretazine 57 ancrod 57 NATRECOR R 57 NEVO ™ 57 elotuzumab 57 pertuzumab 57 pharmacodynamics PD 57 nonrandomized 57 teduglutide 57 valopicitabine 57 ELND# 57 pharmacokinetic PK study 57 dose cohorts 57 EOquin TM 57 pharmacodynamic effects 57 Triolex 57 PIX# [002] 57 Alocrest 57 pharmacokinetic profile 57 Onbrez Breezhaler 57 adjuvant colon cancer 57 placebo controlled clinical 57 melphalan prednisone 57 diabetic neuropathic pain 57 CINTREDEKIN BESUDOTOX 57 achieved statistical significance 57 PRT# 57 primary hypercholesterolemia 57 LEP ETU 57 LibiGel Phase III 57 Golimumab 57 bardoxolone 57 mRCC 57 dirucotide 57 MYDICAR 57 FOLPI 57 REVLIMID lenalidomide 57 CA4P 57 apremilast 57 Traficet EN 57 maximally tolerated dose 57 tolerated dose MTD 57 Fibrillex TM 57 TYZEKA 57 placebo controlled Phase 57 urate lowering 57 ezogabine 57 zalutumumab 57 CRMD# 57 commercialization milestones 57 CIMZIA TM 57 RSD# oral 57 pharmacodynamic properties 57 QTc prolongation 57 Phase 2a clinical 57 REMICADE ® 57 PNH patients 57 docetaxel Taxotere ® 57 XL# XL# XL# XL# 57 preclinical pharmacokinetic 56 pegloticase 56 L MTP PE 56 GLIADEL R Wafer 56 double blinded placebo 56 galiximab 56 GOUT 56 eprotirome 56 cangrelor 56 ORMD 56 Zerenex 56 MEND CABG 56 dose regimens 56 glufosfamide 56 huC# DM4 56 6R BH4 56 AVE# 56 trastuzumab DM1 56 Marqibo 56 Amrubicin 56 Fibrin Pad 56 phase IIIb 56 clinically meaningful differences 56 ICA # 56 randomized clinical trials 56 ADAGIO study 56 TAXUS Stent 56 Phase IIa trial 56 R#/MEM # 56 Bronchitol 56 HGS ETR2 56 randomized controlled clinical trials 56 evaluable patients 56 tolerability pharmacokinetics 56 CHAMPION PLATFORM 56 tezampanel 56 SPIRIT FIRST 56 eliglustat tartrate 56 SCH # 56 Zemplar Capsules 56 tolevamer 56 TOLAMBA 56 PROactive study 56 ascending dose 56 pexelizumab 56 MAGE A3 ASCI 56 Canvaxin TM 56 Phase 2b clinical 56 MGN# 56 aflibercept 56 plasma pharmacokinetics 56 Pharmacokinetic PK 56 febuxostat 56 Onrigin 56 HCV RESPOND 2 56 NATRECOR ® 56 ambrisentan 56 ADVEXIN therapy 56 certolizumab 56 lymphoma CTCL 56 EOquin 56 dose escalation Phase 56 DAPT 56 HGS ETR1 56 ularitide 56 Phase IIIb clinical 56 novel VDA molecule 56 Board DSMB 56 SYMMETRY trial 56 PRIMO CABG2 56 FOSRENOL R 56 RE SURGE 56 motesanib 56 PEG Interferon lambda 56 Efficacy endpoints 56 Mylotarg 56 non selective NSAIDs 56 levosimendan 56 Onrigin TM 56 Fludara 56 Phase #b/#a clinical 56 Phase IIB 56 MERLIN TIMI 56 tezampanel NGX# 56 trospium 56 axitinib 56 therapeutic regimens 56 Phase IIa clinical 56 Octreolin 56 low dose cytarabine 56 RCTs 56 CoFactor 56 Ophena TM 56 Androxal 56 clinical pharmacology studies 56 INVEGA ® 56 dacetuzumab 56 Phase 1a 56 serum phosphorous 56 Phase III confirmatory 56 FTY# 56 celgosivir 56 KRAS status 56 optimal dosing 56 oral prodrug 56 colesevelam HCl 56 baminercept 56 biologic therapy 56 vidofludimus 55 Allovectin 7 R 55 mGluR5 NAM 55 oblimersen 55 mCRC patients 55 cannabinor 55 crizotinib PF # 55 oral FTY# 55 brostallicin 55 EURIDIS 55 GFT# 55 clevidipine 55 EDEMA3 trial 55 oral rivaroxaban 55 GRNCM1 55 prospective multicenter randomized 55 cardiovascular morbidity 55 interferon gamma 1b 55 dosing cohorts 55 temsirolimus 55 alvespimycin 55 satraplatin Phase 55 imatinib therapy 55 NGX# 55 ATACAND 55 endpoints 55 peg interferon 55 Events MACE 55 RGB # 55 limiting toxicity 55 Cloretazine R VNP#M 55 CR# vcMMAE 55 TELINTRA 55 safinamide 55 rALLy 55 Phase 1b 55 LEVADEX 55 ganetespib 55 successfully commercialize Iluvien 55 vismodegib 55 PROMACTA 55 adalimumab 55 genotypic resistance 55 ADVEXIN clinical 55 lanthanum carbonate 55 GLP toxicology studies 55 FOLOTYN 55 placebo controlled 55 Aflibercept 55 clinically meaningful efficacy 55 NSABP C 55 angiographic outcomes 55 unblinded 55 tocilizumab 55 calcineurin inhibitors 55 varespladib 55 COMFORT II 55 pharmacokinetic pharmacodynamic 55 timepoint 55 CANCIDAS 55 Excellarate 55 budesonide MMX 55 confirmatory Phase III 55 Anturol 55 RIGScan CR 55 CYT# 55 ELACYT 55 #mg QD [001] 55 virologic response 55 iniparib 55 dirucotide MBP# 55 ARCOXIA 55 Pemetrexed 55 edoxaban 55 placebo controlled randomized 55 Amigal 55 multicenter Phase 55 pitavastatin 55 Capesaris 55 peginesatide 55 chronic angina 55 OPAXIO 55 budesonide foam 55 bivalirudin 55 Targretin 55 Tarceva TM 55 randomized blinded 55 MADIT II 55 mg dose 55 lipid lowering agents 55 Taxotere R 55 Secondary endpoints included 55 LUNESTA 55 Tekamlo 55 elacytarabine 55 AVANDIA 55 Prostate AdenoCarcinoma Treatment 55 Zelrix 55 OvaRex R 55 Cethromycin 55 Synavive 55 Zoraxel 55 investigational monoclonal antibody 55 velafermin 55 pralatrexate 55 systemically administered 55 1mg dose 55 ruboxistaurin 55 virologic 55 YONDELIS 55 Aryplase 55 demonstrated statistically significant 55 virological response 55 APTIVUS 55 anti leukemic 55 IOP lowering 55 dose cohort 55 randomized #:#:# 55 Acetavance 55 RoACTEMRA 55 nalbuphine ER 55 Phase IIIb 55 octreotide implant 55 Tasimelteon 55 monotherapy 55 sunitinib 55 ISTODAX 55 evaluating REVLIMID 55 tapentadol ER 55 Phase Ib clinical 55 FOSRENOL ® 55 #mg BID [003] 55 multicentre randomized 55 obatoclax 55 PSN# [002] 55 placebo controlled Phase III 55 SEPET TM 55 refractory Hodgkin lymphoma 55 Proxinium TM 55 prospective randomized placebo 55 fluoropyrimidine 55 prospective randomized multicenter 55 senicapoc 55 adjuvant GIST 55 Azedra TM 55 sorafenib Nexavar 55 Zenvia ™ 55 ATL# [001] 55 mg kg dose 55 eltrombopag 55 TORISEL 55 Virulizin ® 55 CTAP# Capsules 55 bosutinib 55 dose escalation 54 Panzem R NCD 54 SPIRIVA HandiHaler 54 postmarketing surveillance 54 ongoing Phase 1b 54 antitumor activity 54 endoscopic remission 54 pharmacokinetics 54 ticagrelor 54 rapid virologic response 54 Plicera 54 lipid parameters 54 phase IIb study 54 rNAPc2 54 amrubicin 54 Prosaptide 54 PFO migraine 54 TBC# 54 pharmacodynamic profiles 54 vinorelbine 54 OMNARIS HFA 54 enoximone 54 Navelbine ® 54 MOZOBIL 54 Asentar 54 patients evaluable 54 statistically significant improvement 54 micafungin 54 lucinactant 54 oral taxane 54 nilotinib 54 Candesartan 54 Chrysalin 54 BLA submission 54 FOLFOX4 54 BEMA Buprenorphine 54 Q#IR 54 denufosol 54 Phase 1a clinical 54 randomized discontinuation trial 54 Xinlay 54 HBeAg positive patients 54 ACCLAIM trial 54 hemostatic efficacy 54 Phase III clinical 54 R# #mg BID 54 EGFR HER2 54 Eliquis 54 daclizumab 54 cystinosis patients 54 mg doses 54 Bicifadine 54 Ereska 54 Doxil ® 54 ONGLYZA 54 APTIVUS r 54 CINQUIL 54 aclidinium 54 antipsychotic efficacy 54 ORENCIA ® 54 multicenter Phase III 54 Phase IIb clinical 54 DASISION 54 Phase 2b trial 54 everolimus eluting stents 54 confirmatory clinical 54 Dual Opioid 54 IMPROVE HF 54 RE LY 54 pharmacokinetic characteristics 54 assessing T DM1 54 Phase Ib II 54 oxymorphone ER 54 endoscopic gastric ulcers 54 carotid artery stenting 54 abatacept 54 prospective randomized controlled 54 PEGylated interferon beta 1a 54 tofacitinib 54 CLARITY study 54 trastuzumab emtansine T DM1 54 dosing cohort 54 lumiracoxib 54 dexanabinol 54 rivaroxaban 54 COU AA 54 Vidaza azacitidine 54 azacitidine 54 QAB# 54 Stedivaze 54 Anturol TM 54 indiplon capsules 54 randomized controlled 54 CEQ# 54 headache nasopharyngitis 54 prognostic variables 54 romidepsin 54 metastatic castration resistant 54 immunogenicity 54 Phase IIb trial 54 HspE7 54 clinically meaningful improvement 54 EDEMA3 54 reslizumab 54 morphometric vertebral fractures 54 MGCD# [001] 54 PEG INTRON 54 Sulonex 54 almorexant 54 Vilazodone 54 TRIOLEX 54 relapsed SCLC 54 ANCHOR trial 54 rolofylline 54 TroVax 54 ocular formulation 54 TLK# 54 Ceflatonin 54 OvaRex ® MAb 54 pharmacodynamic markers 54 MGCD# [002] 54 Entereg 54 5-fluorouracil/leucovorin 54 ONGLYZA ™ 54 ToGA 54 QNEXA 54 Neurodex 54 Ceplene/IL-2 54 dose proportionality 54 clinical trial 54 aliskiren 54 predefined criteria 54 NovoTTF 54 GLYX 54 BEXXAR Therapeutic Regimen 54 Phase #/#a 54 bevacizumab Avastin ® 54 dosage regimen 54 mycophenolate mofetil 54 BrachySil TM 54 Welchol 54 arzoxifene 54 Ozarelix 54 investigational compounds 54 pirfenidone 54 INCB# [002] 54 ponatinib 54 metastatic RCC 54 IIIa inhibitor 54 systemic immunosuppressive drugs 54 multicenter Phase II 54 blinatumomab 54 eculizumab therapy 54 ASA# 54 registrational 54 Tolerability 54 Dyloject TM 54 antiarrhythmic drug 54 chlorambucil 54 GENASIS trial 54 decitabine 54 Panzem R 54 LAF# 54 OncoVEX GM CSF 54 PF # [001] 54 inhaled iloprost 54 otelixizumab 54 DexaSite 54 LymphoStat B 54 SABCS 54 evaluable subjects 54 candesartan cilexetil 54 DU #b 54 Pharmacokinetic 54 Phase 1b trial 54 CYT# potent vascular disrupting 54 Soliris TM eculizumab 54 Torisel 54 Phase 1b clinical 54 Phase 2b kidney transplant 54 anti angiogenic agents 54 CTEPH 54 randomized trials 54 ribavirin RBV 54 ADVANCE PD 54 randomized multicenter 54 AVADO 54 FM VP4 54 VIAject R 53 randomized Phase III 53 SIMPADICO 53 vildagliptin 53 Contrave# 53 BYDUREON 53 LibiGel ® 53 Taxotere ® 53 Elitek 53 prespecified secondary 53 AEGR 53 ascending doses 53 insulin detemir 53 KIACTA ™ 53 TYKERB 53 randomized clinical 53 VELCADE melphalan 53 GEM OS1 53 tipranavir 53 omecamtiv mecarbil 53 PREOS 53 Phase III pivotal 53 pramlintide metreleptin combination 53 liposomal doxorubicin 53 multicenter randomized 53 alteplase 53 EXPAREL ™ 53 neurologic progression 53 bovine thrombin 53 acute coronary syndromes ACS 53 recurrent glioblastoma multiforme 53 Plenaxis TM 53 Azedra ™ 53 ONTARGET 53 undetectable HBV DNA 53 AQ4N 53 TNF antagonist 53 ISENTRESS 53 trastuzumab Herceptin R 53 NEUVENGE 53 BENICAR HCT 53 ELADUR 53 Solid Tumors criteria 53 statistical significance p 53 Phase 2a 53 bardoxolone methyl 53 PERSEUS 53 telcagepant 53 adjuvant therapies 53 Thrombolysis 53 comparator arm 53 SILENOR ™ 53 tgAAC# 53 HORIZONS AMI trial 53 AGILECT R 53 ZYBRESTAT fosbretabulin 53 SVR# 53 OXi# 53 olmesartan 53 clinical trials Multikine 53 TYGACIL 53 ALN TTR# 53 Corlux 53 dacarbazine 53 Augment Injectable 53 erlotinib Tarceva ® 53 SPIRIT III 53 taxane resistant 53 NV1FGF 53 docetaxel Taxotere R 53 canakinumab 53 SNRI 53 indacaterol 53 enzastaurin 53 HMG CoA reductase inhibitors 53 CYPHER R Sirolimus eluting 53 DAVANAT 53 Pivotal Phase III 53 refractory chronic lymphocytic 53 refractory AML 53 CIMZIA R 53 squalamine 53 IL# PE#QQR 53 multicenter placebo controlled 53 AVERROES 53 clinically relevant 53 novel histone deacetylase 53 prophylactic therapy 53 Phase IIa 53 dacarbazine chemotherapy 53 IMPACT IMmunotherapy 53 AeroLEF TM 53 Imprime PGG 53 Pimavanserin 53 postoperative ileus POI 53 RHUCIN 53 lomitapide 53 remission CR 53 death reinfarction 53 CBLC# 53 casopitant 53 preclinical studies 53 plus prednisone 53 dose escalation phase 53 Cloretazine ® 53 thorough QT 53 irbesartan 53 Tolvaptan 53 Committee IDMC 53 lubiprostone 53 ischemic cardiomyopathy 53 Onalta ™ 53 Zybrestat 53 undetectable HCV RNA 53 subcutaneous PRO 53 statistically significant superiority 53 octreotide 53 tumor progression TTP 53 mcg dose 53 carboplatin paclitaxel 53 patients undergoing percutaneous 53 paclitaxel eluting stents 53 randomized placebo controlled 53 Genz # 53 PRECISE 53 thrombolytic agents 53 Cleviprex TM clevidipine 53 coadministration 53 lipid lowering therapies 53 Tumor Response 53 sapacitabine 53 vandetanib 53 Initiated Phase 53 prostate cancer CRPC 53 briakinumab 53 unresectable 53 IPLEX 53 randomized controlled clinical 53 CoreValve System 53 PRISTIQ 53 RezularTM 53 YERVOY 53 AGGRASTAT R 53 davunetide intranasal AL 53 Urocortin 2 53 torezolid phosphate 53 liver metastases 53 NOXAFIL Oral Suspension 53 Oral NKTR 53 Sandostatin LAR 53 prGCD 53 ARIXTRA 53 sirolimus eluting stents 53 Zometa zoledronic acid 53 GnRH agonist 53 Phase III 53 ASCEND HF 53 randomized controlled trials 53 TAXUS Liberte Stent 53 alicaforsen enema 53 thromboembolic events 53 rindopepimut 53 methylnaltrexone 53 GEM OS2 53 limiting toxicity DLT 53 Edwards SAPIEN valve 53 Navelbine 53 Ocrelizumab 53 vicriviroc 53 biodistribution 53 OMS#HP 53 ospemifene 53 safety tolerability pharmacokinetic 53 TASKi3 53 EchoCRT 53 Secondary endpoints include 53 ADVEXIN 53 TNF alpha inhibitor 53 CHAMPION PCI 53 NEUMUNE 53 ozarelix 53 Microplasmin 53 Archexin 53 JANUVIA 53 eprodisate Fibrillex TM 53 meta analyzes 53 intravesical 53 optimal dosing regimen 53 fluvastatin 53 Zenvia Phase III 53 fondaparinux 53 metastatic HRPC 53 unresectable HCC 53 midstage clinical trials 53 Afatinib 53 KNS # 53 β blockers 53 sNDA submission 53 TKM ApoB 53 ENDEAVOR IV 53 Itopride 53 Ostarine 53 abiraterone acetate 53 retinal thickness 53 intravesical therapy 53 Phase 2b 53 MBP# [001] 53 Psoriasis Area 53 Phase Ib clinical trials 53 XP# XP# 53 trastuzumab DM1 T DM1 53 ExTRACT TIMI 53 tasocitinib 53 APEX PD 53 surrogate markers 53 IPX# 53 mg BID 53 weekly subcutaneous injections 53 RELOVAIR ™ 53 Phase IIa clinical trials 53 dextromethorphan quinidine 53 ACCORD Lipid 53 olanzapine LAI 53 QTinno 53 carotid stenting 53 systemic ALCL 53 HuMax EGFr 53 Inhalation Solution 53 clinical trials 53 ENDEAVOR III 53 renal toxicity 53 rosuvastatin #mg 53 NOX E# 53 PEARL SC 53 antihypertensive agents 53 antidiabetic drugs 53 Resolute DES 53 TLUS 53 FOLOTYN ® 53 NEO3 53 potency selectivity 53 zonisamide SR 53 Phase IIb III 53 Carfilzomib 53 non metastatic osteosarcoma 53 sodium thiosulfate STS 53 warfarin therapy 53 dose escalation study 53 sustained virologic response 53 RAPAFLO R 53 relapsed refractory multiple myeloma 53 T Pred 53 rt PA 53 Pegasys ® 53 Adalimumab 53 CRx 53 Heplisav 53 concomitant medications 53 Aclidinium 53 randomized controlled trials RCTs 53 AZILECT ® 53 HZT 53 Phase IIb clinical trials 53 GVAX 53 icatibant 53 EXJADE 53 Sym# 53 synthetic retinoid 53 ALVESCO 53 rFVIIa 53 BRIM2 53 PRECiSE 53 iclaprim 53 Tekturna HCT 53 IMC A# 53 PDX pralatrexate 53 #mg BID [001] 53 PrevOnco ™ 53 prospective observational studies 53 panitumumab 53 MKC# PP 53 lintuzumab SGN 53 pharmacodynamics 53 atrasentan 52 Phase IIa trials 52 MAXY alpha 52 EGFR antibodies 52 mertansine 52 ACE inhibitor ramipril 52 Phase IIb Clinical Trial 52 registrational trial 52 SNT MC# 52 ustekinumab 52 SYNTAX trial 52 Endpoints 52 Genasense ® oblimersen 52 SinuNase 52 chemoradiotherapy 52 trial evaluating PRX# 52 GALNS 52 ZYBRESTAT 52 Topical Interferon Alpha 2b 52 ROCKET AF 52 PLK1 SNALP 52 antithrombotic 52 Arikace 52 ecallantide 52 relapsed MM 52 symptomatic VTE 52 APPRAISE 52 Bezielle 52 receptor tyrosine kinase inhibitor 52 ORENCIA R 52 tiotropium 52 Phase III trials 52 Contrave 52 MYCAMINE 52 Troxatyl 52 metabolic parameters 52 ENDEAVOR II 52 EVIZON 52 Vicinium TM 52 metastatic CRC 52 Glufosfamide 52 serum phosphorus 52 MitraClip device 52 radiolabeled TM# 52 PRECISE trial 52 MoxDuo TM IR 52 TPI ASM8